Dino Tarabar

Anti-MAdCAM antibody (PF-00547659) for ulcerative colitis (TURANDOT): a phase 2, randomised, double-blind, placebo-controlled trial

Séverine Vermeire, William J. Sandborn, Silvio Danese et al. · The Lancet · 2017 · 197 citations

Inflammation, Autoimmune Disease, Mucosal Immunology +9

Phase II evaluation of anti-MAdCAM antibody PF-00547659 in the treatment of Crohn’s disease: report of the OPERA study

William J. Sandborn, Scott D. Lee, Dino Tarabar et al. · Gut · 2017 · 107 citations · Full text

Phase 2: a dose-escalation study of OncoGel (ReGel/paclitaxel), a controlled-release formulation of paclitaxel, as adjunctive local therapy to external-beam radiation in patients with inoperable esophageal cancer

G.A. DuVall, Dino Tarabar, Richard Seidel et al. · Anti-Cancer Drugs · 2009 · 79 citations

Dose-escalation Study, Injection Site, Radiation Medicine +14

Onercept for Moderate-to-Severe Crohn’s Disease: A Randomized, Double-Blind, Placebo-Controlled Trial

Paul Rutgeerts, William J. Sandborn, Richard N. Fedorak et al. · Clinical Gastroenterology and Hepatology · 2006 · 66 citations

Anti-inflammatory, Functional Gastrointestinal Disorder, Pharmacology +5

Efficacy and safety of 48 weeks of guselkumab for patients with Crohn's disease: maintenance results from the phase 2, randomised, double-blind GALAXI-1 trial

Silvio Danese, Remo Panaccione, Brian G. Feagan et al. · ˜The œLancet. Gastroenterology & hepatology · 2023 · 61 citations

Urology, Moxibustion, Gastroenterology +6